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Recent advances toward a molecular
mechanism of efflux pump inhibition
Timothy J. Opperman* and Son T. Nguyen
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Multidrug resistance (MDR) in Gram-negative pathogens, such as the Entero-
bacteriaceae and Pseudomonas aeruginosa, poses a significant threat to our ability
to effectively treat infections caused by these organisms. A major component in the
development of the MDR phenotype in Gram-negative bacteria is overexpression
of Resistance-Nodulation-Division (RND)-type efflux pumps, which actively pump
antibacterial agents and biocides from the periplasm to the outside of the cell.
Consequently, bacterial efflux pumps are an important target for developing novel
antibacterial treatments. Potent efflux pump inhibitors (EPIs) could be used as adjunctive
therapies that would increase the potency of existing antibiotics and decrease the
emergence of MDR bacteria. Several potent inhibitors of RND-type efflux pump have
been reported in the literature, and at least three of these EPI series were optimized
in a pre-clinical development program. However, none of these compounds have been
tested in the clinic. One of the major hurdles to the development of EPIs has been
the lack of biochemical, computational, and structural methods that could be used to
guide rational drug design. Here, we review recent reports that have advanced our
understanding of the mechanism of action of several potent EPIs against RND-type
pumps.
Keywords: efflux pump inhibitor, mechanism of action, RND family pumps, AcrB, AcrD, MexB, Escherichia coli,
Pseudomonas aeruginosa
Introduction
The rise of multidrug resistant (MDR) Gram-negative pathogens poses a signiﬁcant clinical prob-
lem. Apart from the acquisition of acquired resistance traits, such as transposons and plasmids
encoding proteins that inactivate antibiotics, many of these organisms have increased resistance
resulting from mutations that alter the expression of genes that are involved in intrinsic resistance
to antibiotics (Nikaido and Pages, 2012). One of the major contributors to intrinsic resistance
in Gram-negative bacteria are eﬄux pumps of the Resistance-Nodulation-Division (RND) fam-
ily eﬄux in Gram-negative bacteria, which extrude a broad spectrum of antibiotics and biocides,
including the ﬂuoroquinolones (e.g., ciproﬂoxacin and levoﬂoxacin), β-lactams (e.g., piperacillin,
meropenem, and aztreonam; Piddock, 2006), tetracyclines (minocyline), oxizolidinines (linezolid),
and β-lactamase inhibitors (e.g., clavulanate and sulbactam; Li et al., 1998; Nakae et al., 2000), from
the periplasm to the outside of the cell. Because of their broad-substrate speciﬁcity, overexpression
of the RND eﬄux pumps results in decreased susceptibility to diverse array of antibacterial agents
and biocides (Nikaido and Pages, 2012). In addition, elimination of RND pumps in Pseudomonas
aeruginosa by genetic deletion (Lomovskaya et al., 1999) or inhibition with a potent eﬄux pump
inhibitor (EPI; Lomovskaya et al., 2001) decreases the frequency of resistance to levoﬂoxacin.
Frontiers in Microbiology | www.frontiersin.org 1 May 2015 | Volume 6 | Article 421
Opperman and Nguyen Efflux pump inhibitor mechanism
In Escherichia coli, a functional RND pump (AcrAB-TolC) is
required for the selection of mutations in the targets of ﬂuo-
roquinolones (gyrA and gyrB) that give rise to ﬂuoroquinolone
resistance (Singh et al., 2012). Furthermore, RND pumps have
been shown to play a role in virulence of the enteric pathogen
Salmonella enterica serovar Typhimuirum (Nishino et al., 2006),
and EPIs that target RND pumps have been shown to inhibit
bioﬁlm formation in E. coli and Klebsiella pneumoniae (Kvist
et al., 2008). Therefore, EPIs could be useful as adjunctive ther-
apies with an antibiotic to improve antibacterial potency at
low antibiotic concentrations, reduce the emergence of resis-
tance, inhibit bioﬁlm formation, and decrease virulence of enteric
pathogens. Consequently, there has been considerable interest in
developing EPIs of the RND family pumps.
Several potent EPIs that target the RND family pumps have
been described in the literature (Van Bambeke et al., 2006),
however, none have reached clinical development. A family of
peptidomimetics, including PAβN (MC-207 110), that exhibited
potent inhibition of eﬄux pumps in P. aeruginosa has been devel-
oped for use as an adjunctive therapy (Renau et al., 1999, 2001,
2002, 2003; Lomovskaya et al., 2001; Watkins et al., 2003). Some
of these inhibitors were validated using in vivo infection mod-
els (Renau et al., 1999, 2001; Watkins et al., 2003), however, they
were abandoned because of toxicity (Lomovskaya and Bostian,
2006). The positive charged moieties that were required for activ-
ity in P. aeruginosa caused nephrotoxicity. In addition, a series
of pyridopyrimidine EPIs that are speciﬁc for the MexAB eﬄux
pump of P. aeruginosa was advanced to the preclinical stage
(Nakayama et al., 2003a,b, 2004a,b; Yoshida et al., 2006a,b, 2007).
However, the development of this series appears to have been
halted. Finally, a pyranopyridine EPI, MBX2319, with potent
activity against Enterobacteriaceae, but low activity vs. P. aerugi-
nosa, has been described recently (Opperman et al., 2014). This
compound is in the early stages of lead optimization and has
not been tested for eﬃcacy in animal models of infection. The
diﬃculties encountered during the development of these varied
classes of EPIs underscore some of the most signiﬁcant challenges
for developing EPIs for clinical use: potency, spectrum of activity,
pharmacokinetics, and toxicity. Detailed knowledge of the mode
of inhibition and the binding site of an EPI could facilitate the
rational design of analogs with properties that could address these
challenges.
There are signiﬁcant challenges to mechanism of action
(MOA) studies for EPIs vs. the RND family eﬄux pumps, many
of which complicate their discovery and development. One of
the major challenges is the structural complexity of the RND
pumps, which are an integral membrane (IM)molecular machine
that spans the inner membrane, periplasmic space, and the outer
membrane. The RND family eﬄux pumps comprise a tripartite
structure, consisting of an IM eﬄux transporter with broad-
substrate speciﬁcity, an outer membrane channel that carries
substrates from the pump through the outer membrane, and a
periplasmic adapter protein. Themajor RNDpumps in E. coli and
P. aeruginosa are AcrAB-TolC and MexAB-OprM, respectively;
AcrB/MexB are the IM pumps, AcrA/MexA are the membrane
adapter protein, and TolC/OprM form the channel through the
outer membrane. The pump subunits (AcrB and MexB) consist
of the following domains: (1) an IM domain comprised of 12
transmembrane helices that utilizes proton-motive force to drive
the pumping action; (2), a porter domain comprised of the two
large periplasmic loops that binds and extrudes substrates, and
(3) a cap domain that binds to TolC [reviewed in Blair and
Piddock (2009), Eicher et al. (2009), Pos (2009), Nikaido and
Pages (2012)]. The three-dimensional structure of AcrB was ﬁrst
described as a symmetrical trimer, in which all subunits were in
the same conformation (Murakami et al., 2002). Subsequently, an
asymmetrical three-dimensional structure of AcrB was described
(Murakami et al., 2006; Seeger et al., 2006; Sennhauser et al.,
2007), in which the conformation of each subunit was diﬀerent.
Several lines of evidence indicate that the asymmetrical struc-
ture represents the biologically relevant form of the pump (Seeger
et al., 2008; Takatsuka and Nikaido, 2009; Eicher et al., 2014).
The conformations of the three subunits of the pump have been
described as the Access (loose), Binding (tight), and Extrusion
(open) subunits. The current model for the mechanism of the
RND pumps is that each conformation represents a distinct step
in the translocation pathway, in which each subunit successively
assumes each of the conformations as substrates ﬁrst interact with
the pump in the Access conformation, are moved to the sub-
strate binding pocket in the Binding conformation, and are then
extruded into a central channel that leads to TolC as the bind-
ing pocket collapses en route to the Extrusion conformation. The
entire process is driven by proton-motive force that is transduced
by the IM domain of the protein (Su et al., 2006; Seeger et al.,
2009; Takatsuka and Nikaido, 2009).
Of particular interest to the design of EPIs is the structure of
the substrate binding pocket in the Binding protomer, also known
as the distal binding site. The broad-substrate speciﬁcity of AcrB
and MexB suggested that the substrate binding site would exhibit
unique features that enable polyspeciﬁc, but not non-speciﬁc,
binding of substrates. The substrate binding pocket was clearly
deﬁned when the three-dimensional structures of the asymmetric
AcrB trimer with two pump substrates, minocycline and doxoru-
bicin, bound to the Binding protomer were reported (Murakami
et al., 2006). The substrate binding pocket comprised a large
cavity lined with hydrophobic (Phe136 and Phe178, Phe610,
Phe615, Phe617, and Phe628) and polar residues (Asn274 and
Gln176). Minocycline and doxorubicin interacted with a distinct
set of amino acid residues that line the deep binding pocket
in the “Binding” subunit. Both compounds interacted mainly
with hydrophobic residues through Van der Waals and ring-
stacking interactions, and made hydrogen bonding interactions
with the polar residues. However, minocycline and doxorubicin
bound to slightly diﬀerent regions of the binding pocket. Thus,
the structure of the binding pocket with substrates explains the
broad-substrate speciﬁcity of the pump, which is characterized
by interactions based on generalized physical properties, such as
hydrophobicity, and low binding aﬃnities. Consequently, devel-
oping inhibitors that can bind to this site with high aﬃnity is a
major challenge.
Despite complexities of the RND family pumps, progress
toward a better understanding of the MOA of several EPIs has
been made on several fronts. In this article, we will review two
aspects of the MOA studies of the major EPIs. Thus, the review
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will be divided in two parts. First, we will review the various tech-
nologies that have been used to study the structure and function
of RND family eﬄux pumps and how they have been, or could
be applied to study the mechanism of EPIs. The technologies
that will be discussed include genetic, biochemical, structural,
and computational approaches. Second, we will review the major
classes of EPIs in terms of their biological activities, stage of
development, and what is known about their MOA, including at
least three important developments. These include the ﬁrst crys-
tal structure of an EPI bound to two RND pumps (Nakashima
et al., 2013), the ﬁrst report of EPI-resistant mutants that map
to the binding site of AcrB (Schuster et al., 2014), and the appli-
cation of molecular dynamic (MD) simulations to model the
binding sites of other EPIs (Vargiu and Nikaido, 2012; Vargiu
et al., 2014).
Approaches to Study the Mechanism
of Action of EPIs
Genetic Studies
The classic method for identifying the molecular target of an
antibacterial agent is the select for resistant mutants and to map
the mutations to the putative target. However, in the case of EPIs,
this approach has proven to be very diﬃcult for the following
reasons. Because the majority of EPIs do not exhibit antibacte-
rial activity, resistant mutants cannot be selected directly. Instead,
mutants resistant to the EPI must be selected in the presence of
an antibiotic or biocide that is a substrate of the pump, which
provides the selective pressure. The selection for EPI-resistant
mutants usually consists of an EPI and antibiotic at concen-
trations that would enable growth if a mutation resulted in
resistance to the EPI. This selection scheme creates two prob-
lems. First, since the EPI and the antibiotic bind to the substrate
binding pocket, it is possible that mutations result in decreased
aﬃnity for the EPI also reduce aﬃnity for the antibiotic. This
is particularly problematic for EPIs that are pump substrates or
competitive inhibitors that bind to the same or an overlapping
site in the binding pocket. Second, the presence of an antibi-
otic in the selection results in a high background of mutants
with decreased susceptibility to the antibiotic due to mutations
in genes that encode the antibiotic target or another intrinsic
resistance mechanism, such as antibiotic inﬂux (porin). Third,
if EPI-resistant mutants are obtained in such a screen, they
may be speciﬁc for the antibiotic used for selection. Finally, it
is likely that the structure of the substrate binding pocket of
the RND family pumps, which is large and contains potentially
overlapping binding sites, decreases the probability of identify-
ing resistant mutants. Indeed, site-directed mutations aﬀecting
the residues that were shown to interact with minocycline or
doxorubicin in co-crystal structures do not signiﬁcantly aﬀect
the minimal inhibitory concentrations (MICs) for these drugs,
suggesting a plasticity in their interactions with the substrate
binding pocket (Bohnert et al., 2008). Consequently, there have
been no reports of the isolation of spontaneous EPI-resistant
mutations in RND-family pumps (Lomovskaya and Bostian,
2006).
Site-directed mutagenesis and construction of hybrid pumps
were used to map the substrate binding domain and the deter-
minants of binding speciﬁcity. To map the substrate binding
sites and determinants of substrate speciﬁcity, Elkins and Nikaido
(2002) constructed chimeric pumps in which the periplasmic
loops of AcrD and AcrB were replaced with the corresponding
loops of AcrB and AcrD, respectively. The resulting chimeras
exhibited the substrate speciﬁcities characteristic of the pump
that was the source of the periplasmic loops, indicating that
the functions of substrate binding and speciﬁcity reside in the
periplasmic loops. The exchange of periplasmic loops between
the following AcrB homologs yielded similar results: P. aerugi-
nosa MexB and MexY (Eda et al., 2003), and AcrB and MexB
(Tikhonova et al., 2002). Mao et al. (2002) selected mutants of
AcrD with expanded substrate recognition, which mapped to
the periplasmic loops comprising the porter domain. Kobayashi
et al. (2014) replaced portions of the access binding site of AcrB
with corresponding non-conserved portions of AcrD to iden-
tify residues that are responsible for the selectivity of AcrD for
anionic β-lactam antibiotics, such as aztreonam, carbenicillin,
and sulbenicillin. Building on the results of these studies, the
authors used site-directed mutagenesis to construct an AcrB
pump that conferred high-level resistance to anionic β-lactam
antibiotics, a characteristic of AcrD. In addition, site-directed
mutants of AcrB have been constructed to map residues in the
deep binding pocket that play a key role in substrate recogni-
tion and extrusion (Bohnert et al., 2008). However, these types of
experiments have not been used to determine residues important
for the binding of EPIs.
In contrast, mutations responsible for EPI resistance were
identiﬁed in bmr, a broad-substrate speciﬁcity eﬄux pump in
Bacillus subtilis of the major facilitator superfamily (MFS), that
reduced aﬃnity for an inhibitor (reserpine), but did not aﬀect
aﬃnity for the substrate (ethidium bromide; Ahmed et al., 1993).
This was accomplished by randomly mutagenizing a strain car-
rying a plasmid-encoded copy of bmr, followed by a selection for
mutants consisting of a serial passage in the presence of ethid-
ium bromide and increasing concentrations of reserpine. The
mutations were mapped to bmr and resulted in substitution of
Val296 with Leu. The mutation reduced the aﬃnity of reserpine
for Bmr, but did not aﬀect the eﬄux of ethidium bromide. It
is not clear whether this mutation directly aﬀects binding site
or causes change in conformation that aﬀects binding at a dis-
tance. Since the three-dimensional structure of bmr is not known,
and the substrate binding site has not been identiﬁed, it is dif-
ﬁcult to determine the signiﬁcance of the resistance mutation.
Nevertheless, this study demonstrated that it is possible to gen-
erate and select mutants in an eﬄux pump gene with reduced
susceptibility to an EPI.
The isolation of the ﬁrst EPI-resistance mutations in an RND-
family pump was reported more than 20 years after the bmr
resistance mutations were reported. After attempts to isolate
mutants in E. coli that were resistant to 1-(1-naphthylmethyl)-
piperazine (NMP) and PAβN in a serial passage experiment,
Schuster et al. (2014) randomly mutagenized the two large
periplasmic loops of AcrB using error-prone PCR. They selected
for mutants resistant to NMP and PAβN in combination with
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linezolid or clarithromycin, respectively, in a single step selec-
tion on agar plates. The authors isolated several mutants with
reduced susceptibility to NMP that did not decrease the eﬄux
activity of AcrB. When the NMP-resistant mutations were recon-
structed using site-directed mutagenesis (alone and together),
only a double mutant, in which Gly141 was substituted with Asp
(G141D) and Asn282 was substituted with Tyr (N282Y), signiﬁ-
cantly aﬀected susceptibility to NMP. As shown in Figures 1A,B,
the mutated residues are located near the outer face of the distal
substrate binding pocket near Phe610, which plays an key role in
the extrusion process (Bohnert et al., 2008), and is across from the
so-called “switch-loop” that separates the proximal (access) and
the distal (substrate) binding sites (Nakashima et al., 2011; Eicher
et al., 2012). The authors speculated that the G141D N282Y
amino acid substitutions prevent the binding of NMP to the dis-
tal binding pocket. However, the substituted residues are not near
the binding site of NMP that has been predicted by computa-
tional methods (Vargiu et al., 2014; see Figure 1A, and below
for discussion), suggesting that the mutated residues may inter-
fere with the action of NMP through an alternative mechanism.
Interestingly, the mutated residues reduce susceptibility to NMP
in the presence of linezolid only, the antibiotic used for selection.
This strongly suggests that EPI-resistant mutants isolated in this
type of screen are speciﬁc to the antibiotic used for the selection,
and that the location of the substituted residues cannot be directly
interpreted as being part of the EPI binding site. Because it is not
known whether the NMP-resistant mutant of AcrB has decreased
aﬃnity for NMP, it is possible that the G141D N282Y amino
acid substitutions enable the extrusion of linezolid while NMP
is bound to the deep binding pocket. Further experiments are
needed to fully understand the signiﬁcance of this EPI-resistant
mutant.
Consistent with the experience of other groups, Schuster et al.
(2014) were unable to isolate mutants with reduced susceptibility
to PAβN, a substrate for RND-family pumps (Lomovskaya et al.,
2001; Bohnert et al., 2008). For EPIs that are substrates or com-
petitive inhibitors, mutations that alter the binding site of the EPI
may also aﬀect the aﬃnity for substrates, which could result in cell
death if an antibiotic is used for selection. In addition, the plas-
ticity of the binding site (see above) may also aﬀect EPIs that are
substrates. Although there are only two examples, it is tempting
to speculate that there is a correlation between the mode of inhi-
bition of an EPI and whether it is possible to isolate EPI-resistant
mutations that map to the RND pump.
Biochemical Studies
As mentioned above, the RND pumps are complex IMmachines,
which complicate the biochemical analysis of these proteins.
Nevertheless, the development and use of biochemical systems
for the study of the RND pumps have been reported, however,
none have been used to analyze the mode of inhibition of EPIs.
These studies are summarized below.
Enzyme Activity Assays
Zgurskaya and Nikaido (1999) reported a biochemical system
in which puriﬁed AcrB was reconstituted into proteoliposomes.
Fluorescent derivatives of the lipids phosphatidylethanolamine
labeled with NBD or rhodamine, which are AcrB substrates,
were incorporated into proteoliposomes at concentrations high
enough to for NBD ﬂuorescence to be quenched by rhodamine.
To prevent reincorporation of the substrate into proteoliposome,
unlabeled liposomes were added the reaction mixture to act as
lipid traps for labeled lipid substrate. Therefore, eﬄux activity
results in an increase in the ﬂuorescence of NBD. The eﬄux activ-
ity was dependent on the presence of a transmembrane proton
gradient, and was stimulated by addition of AcrA through an
unknown mechanism. The addition of known pump substrates
inhibited eﬄux of labeled lipids through competition. The bile
salts taurocholate and glycocholate were the strongest inhibitors,
with IC50 values ranging between 15 and 20 μM. While this
FIGURE 1 | The most frequently selected mutations that were
isolated after in vitro random mutagenesis of the periplasmic
domain of AcrB and linezolid/NMP selection are located in the distal
binding pocket. (A) The wild type distal binding pocket of AcrB. The side
chains of the wild-type residues that are substituted in the NMP-resistant
mutant are shown as cyan sticks (glycines as cyan spheres), and distal
binding pocket phenylalanine side chains are shown as yellow sticks. The
view of the distal binding pocket is a side view from the periplasmic outer
face. The residues indicated with red circles are predicted to interact with
NMP my molecular dynamic simulations (Vargiu et al., 2014). The location
of the G-loop is indicated by the arrow. The residues indicated by the blue
circles are those substituted in the G141D N282Y double mutant, which
exhibits the strongest NMP-resistant phenotype. (B) The NMP-resistant
distal binding pocket of AcrB. The residues indicated by the blue circles
are those of the G141D N282Y double mutant. Reprinted with permission
from Schuster et al. (2014).
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biochemical system is amenable for the study of EPIs, it does not
appear that this system has been used for this purpose. The rea-
sons for this are not known. However, it is possible that there has
been little interest in such assays, or that the assay is too diﬃcult
to implement.
Cell-Based Efflux Pump Activity Assay
Nagano and Nikaido (2009) developed a cell-based assay that
measures the eﬄux kinetics of the cephalosporin, nitroceﬁn, by
the intact AcrAB-TolC pump. In this assay, the rate of nitroceﬁn
hydrolysis by a periplasmic β-lactamase was measured spec-
trophotometrically. Using the Michaelis–Menten constants for
the β-lactamase (KM and Vmax), the rate of nitroceﬁn hydrol-
ysis (Vh) was used to determine the periplasmic concentration
(Cp) of nitroceﬁn. The rate of nitroceﬁn inﬂux (Vin) across the
OM was determined experimentally as a function of the external
concentration (Co). The diﬀerence between V in and the mea-
sured rate of cephalosporin hydrolysis (Vh) corresponds to the
rate of eﬄux (Ve) by AcrAB-TolC. By plotting Ve against Cp
for nitroceﬁn, a curve that is indicative of Michaelis–Menten
type kinetics was obtained, from which a KM (6 μM) and Vmax
(0.024 nmol/mg/s) were calculated. This assay format is broadly
applicable to any β-lactam antibiotic that is a substrate of the
periplasmic β-lactamases of E. coli (AmpC or TEM-1). Lim and
Nikaido (2010) used this assay to determine the kinetic parame-
ters for several penicillins and cephalosporins. Interestingly, the
penicillins exhibited a stronger aﬃnity for AcrAB-TolC than did
the cephalosporins, and showed a kinetic behavior that indicated
a strong positive cooperativity. Clearly, this assay format could
have a wide utility in the analyses of eﬄux pump substrates and
inhibitors.
The nitroceﬁn assay has been used to estimate the eﬀects
of an EPI (MBX2319) on the kinetic behavior of AcrAB-TolC
(Opperman et al., 2014). The data demonstrated that MBX2319
(0.2 μM) inhibited AcrAB-TolC, and the inhibition was due
mainly to a large (4.4-fold) increase in the KM. Higher concen-
trations of MBX2319 (1–10 μM) completely inhibited nitroceﬁn
eﬄux and prevented kinetic analyses. In contrast, PAβN (1 μM)
had no eﬀect on the eﬄux of nitroceﬁn, suggesting that this com-
pound does not directly aﬀect AcrB function at lower concentra-
tions. The data suggest that MBX2319 competes with nitroceﬁn
for a site in the binding pocket, or decreases its access to the
binding site. This assay has proven to be useful for determining
the eﬀects of EPIs on the kinetic parameters of AcrAB-TolC, and
could possibly used to determine themode of inhibition (compet-
itive, non-competitive, and uncompetitive) of an EPI. In addition,
the assay format could be adopted to measure the half maximal
inhibitory concentration (IC50) of EPIs, which could be used to
evaluate and prioritize experimental EPIs. The assay format has
several advantages. It is versatile and does not require expen-
sive reagents or equipment. However, because it is a cell-based
assay, great care must be taken to control as many variables as
possible to minimize variability. In addition, the calculations for
Vin depend on several values (see Nagano and Nikaido, 2009)
that may change depending on growth conditions or the bacte-
rial strain that is used. Therefore, it is important to verify these
values under the conditions that exist in your laboratory.
Binding Assays
Several research groups have reported binding assays designed
to measure the aﬃnity of various substrates to the puriﬁed AcrB
or MexB. While many of these methods could be used to study
the interactions between EPIs and RND family pumps, there are
only a few reports of these types of experiments. In addition, great
care must be taken when performing or interpreting the results of
these experiments, as the RND pumps are large and havemultiple
hydrophobic sites where non-speciﬁc interactions could occur.
Therefore, proper negative controls should be included in each
experiment.
The most promising technology for binding studies involv-
ing AcrB is isothermal titration calorimetry (ITC). Nakashima
et al. (2013) measured the binding parameters of D13-9001, a
pyranopyrimidine EPI (see below), to puriﬁed AcrB, MexB, and
MexY using ITC. The data for the titration curves of D13-9001
for AcrB and MexB showed saturation at a stoichiometry of 1:1
(compound: trimer), indicating speciﬁc binding interactions. The
KD values of D13-9001 binding AcrB and MexB were 1.15 and
3.57 μM, respectively. In contrast, no saturation binding in the
titration curves for MexY, which is not inhibited by D13-9001,
was observed. Another group used ﬂuorescence polarization (FP)
to study binding of substrate compounds, such as rhodamine 6G
(5.5 ± 0.9 μM), ethidium bromide (8.7 ± 1.9 μM), ciproﬂoxacin
(74.1 ± 2.6 μM), and proﬂavin (14.5 ± 1.1 μM), to AcrB (Su
and Yu, 2007). However, neither of these studies included a nega-
tive control, such as a proton transduction deﬁcient mutant, in
which none of the subunits are in the Binding conformation.
These results indicate that ITC and FP are useful tools for ana-
lyzing the aﬃnity between EPIs and eﬄux pumps; however, they
do not indicate where the EPIs bind to the pump.
An experimental approach has been described, however, that
could be used to identify binding sites for EPIs. This approach
utilizes a pump substrate, usually a ﬂuorescent dye molecule
that carries a moiety that acts as a cross-linking agent by form-
ing a covalent bond with a speciﬁc amino acid side chain,
such as the free sulfhydryl groups in Cys. This method was
initially used to study the substrate binding speciﬁcity of the
RND pump MexD by Mao et al. (2002). They used 2-(4′-
maleimidylanilino)- naphthalene-6-sulphonic acid (MIANS) as
the cross-linking reagent, which becomes ﬂuorescent only after
it reacts with sulfhydryl groups, which enables the cross-linking
reaction to be monitored by increased ﬂuorescence. Amino acid
residues that were predicted to play a role in substrate recog-
nition were substituted with Cys, and the eﬀect of MIANS on
eﬄux of various substrates was measured. The pump was engi-
neered to contain a single Cys residue. This method was later
used to map the entire substrate path in the AcrB pump of E. coli
(Husain and Nikaido, 2010; Husain et al., 2011). In these stud-
ies, residues that were predicted to line the substrate path were
substituted with a Cys residue using site-directed mutagenesis,
and the accessibility of each of these residues to a lipophilic ﬂu-
orescent cross-linking reagent (Bodipy-FL-maleimide) was mea-
sured. In principle, this assay system could be used to map the
binding sites of EPIs through the competitive exclusion of a
ﬂuorescent-cross linking agent by the inhibitor upon binding to
the same site (competitive), or to an allosteric site binding (either
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non-competitive or uncompetitive), which can be monitored by
the accessibility of the Cys to the cross-linking reagent. The dif-
ferent modes of binding can be distinguished upon analysis of
the binding kinetics. Indeed, this approach was used to obtain
experimental support for hypotheses on the mechanism of sub-
strate recognition in the deep binding pocket of AcrB, which
were generated by in silico docking experiments (Takatsuka et al.,
2010). Competition experiments were used to demonstrate that
compounds predicted to bind to the “groove” of the substrate
binding pocket compete with cross-linking reagent for a Cys
residue in the groove, whereas, compounds predicted to bind
lower in the site, or the so-called “cave,” did not compete. A cova-
lently linked AcrB trimer, which would allow construction of
mutant proteins in which a single subunit can assume the “bind-
ing” conformation, could prove to be useful in this type of study
(Takatsuka and Nikaido, 2009; Zgurskaya, 2009). Despite the fact
that this approach could be applied readily to the study of the
interaction of EPIs with AcrB, it does not appear to have been
used for this purpose. One problem with this approach is that
it requires several AcrB variants, in which a single Cys substitu-
tion is introduced at several sites in the access and deep binding
pockets of AcrB. In addition, the ﬂuorescent cross-linking reagent
must be a pump substrate. Fortunately, several such cross-
linking compounds are available, such as MTS-rhodamine (Loo
and Clarke, 2002), BODIPY-FL-maleimide (Husain et al., 2011),
N-ethylmaleimide (Loo and Clarke, 2002; Guan and Kaback,
2007), or monobromobimane (Fluman et al., 2009). Thus, this
approach could prove to be very useful for MOA studies for EPIs.
X-ray Crystallography
Very few co-crystal structures of the asymmetric trimer of AcrB
bound to substrates, and until recently, no co-crystal structures of
an EPI bound to AcrB (see below) have been reported. As men-
tioned above, co-crystal structures for the substrates minocycline
and doxorubicin bound to the deep binding pocket (Murakami
et al., 2006) and erythromycin and rifampicin bound to the access
binding site (Nakashima et al., 2011) of the asymmetric trimer
have been reported. In contrast, several co-crystal structures of
the symmetrical form of AcrB with substrates (ethidium bromide,
rhodamine 6G, ciproﬂoxacin, nafcillin) and one EPI (PAβN; Yu
et al., 2005), as well as linezolid (Hung et al., 2013), have been
published. However, the relevance of these structures is diﬃcult
to interpret as the pump is not in the conformation are that
is relevant biochemically. The paucity of co-crystal structures
is probably the direct result of the diﬃculty in producing co-
crystals. It is possible that the diﬃculties arise from the relatively
low binding aﬃnities of the substrates for the binding site.
Nakashima et al. (2013) reported a major breakthrough in the
ﬁeld when they published the ﬁrst co-crystal structure of the pyri-
dopyrimidine EPI D13-9001 (see Figures 2A,B) bound to AcrB
(E. coli) and MexB (P. aeruginosa). The inhibitor, D13-9001, is
a pyridopyrimidine compound that is a potent inhibitor of AcrB
and MexB, but not of MexY (P. aeruginosa). The hydrophobic
tert-butyl thiazolyl aminocarboxyl pyridopyrimidine moiety of
D13-9001 binds tightly to a narrow depression, referred to as the
hydrophobic trap, in the deep substrate binding pocket in the
“Binding” protomer (see Figures 2A,B). The hydrophilic portion
FIGURE 2 | The three-dimensional structure of the EPI D13-9001
bound to the Binding protomer of AcrB. (A) D13-9001 bound to the
Binding protomer of the asymmetric trimeric AcrB. D13-9001 is drawn using a
yellow space model and is highlighted by the black oval. The integral
membrane (IM), Porter, and Cap domains are indicated on the right side of the
figure. The Binding and Access protomers are indicated at the bottom of the
figure. The Extrusion protomer is not visible. Secondary structure is indicated
as follows: alpha helix (red); beta sheet (green); Loops (black). The figure was
generated by MarvinSpace (ChemAxon Ltd) using PDB ID: 3w9h (Nakashima
et al., 2013). (B) A detailed view of the D13-9001 binding site. The location of
hydrophobic trap is indicated by the orange oval, and amino side chains of
residues that comprise the hydrophobic trap are shown. The molecular
surface of the binding site has been colored based on hydrophobicity (orange)
and hydrophilicity (blue). The D13-9001 structure is depicted as a stick
drawing that is colored according to the atom type as follows: red, oxygen;
yellow, sulfur; dark blue, nitrogen; cyan, carbon; white, hydrogen. This figure
was made by Hiroshi Nikaido (UC Berkeley) using PyMol (Schrödinger).
of the compound extends into to substrate binding groove where
it interacts with polar residues. A detailed description of the bind-
ing site can be found below. The location of the binding site and
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the high aﬃnity of D13-9001 suggested a MOA for this com-
pound. The current hypothesis is that D13-9001 binds tightly to
the hydrophobic trap and prevents the conformational changes
that are needed for the proper activity of the pump (Nakashima
et al., 2013). In addition, the hydrophilic portion of D13-9001
is expected to prevent binding of a wide range of substrates to
the binding cleft. It is not clear why the co-crystal structure of
D13-9001 is the only one that has been published. While it is not
known how many other EPIs have been attempted, it is possible
that D13-9001 has some properties that are amenable to X-ray
crystallography, as relatively standard conditions for formation
of co-crystals were used (Nakashima et al., 2013). However, the
real signiﬁcance of this work lies in the discovery of a binding
site on AcrB for non-competitive (substrate) inhibitors that can
be exploited for rational design of EPIs.
Computational Methods
Because of the biochemical complexity of the RND family pumps
and the diﬃculty of producing co-crystals, many researchers
have turned to computational methods to explore the struc-
ture function relationships of AcrB and MexB. The computa-
tional systems that have been used to study RND family eﬄux
pumps consist of algorithms that are designed to simulate the
molecular interactions and conformational changes that com-
prise the current model for substrate recognition and extrusion.
These systems range from relatively simple algorithms for dock-
ing compounds into the substrate binding pocket to complex
MD simulations. Docking algorithms, such as AutoDock Vina
(Trott and Olson, 2010), utilize the static binding site deﬁned
by a three-dimensional crystal or NMR structure in the absence
of solvent to identify the most energetically favorable binding
pose of a small molecule. In contrast, MD simulations attempt
to reproduce the behavior of real molecules in motion in the
presence of solvent. MD simulation consists of the numerical,
step-by-step, solution of the classical equations of motion for
each atom. A computer model of the protein is prepared from
a three-dimensional protein structure, and the forces acting on
each atom in the system atoms are then estimated using an equa-
tion that includes molecular ‘force ﬁelds,’ which model various
bonded and non-bonded inter-atomic interactions. Several excel-
lent reviews of the methodology of MD simulations for proteins
have been published (Karplus and McCammon, 2002; Durrant
and McCammon, 2011). Advances in technology have increased
the predictive accuracy of these methods. For example, MD sim-
ulations of the enzyme-inhibitor complex between trypsin and
the inhibitor benzamidine have produced binding predictions
in which the root mean square deviation (rmsd) for the bound
inhibitor was less than 2 Å as compared to the crystal struc-
ture (Buch et al., 2011). However, the current MD simulation
methodologies are limited by high computational costs and by
the approximations of the force ﬁelds used in the modeling.
The use of computational methods for the study of RND-
family pumps and EPIs is made possible by the existence of high-
resolution three-dimensional structures of RND-family pumps
with and without substrates, such as AcrB (Murakami et al., 2006;
Sennhauser et al., 2007; Nakashima et al., 2011, 2013) and MexB
(Sennhauser et al., 2009; Nakashima et al., 2013), and supporting
biochemical data. Takatsuka et al. (2010) used docking experi-
ments to examine the interaction of 30 compounds, including
minocycline, doxorubicin, tetracycline, and levoﬂoxacin with the
distal substrate binding site of the binding protomer. They found
that the substrates that were tested are predicted to bind to one
of two regions of the binding pocket: a narrow groove at the dis-
tal end of the pocket, and a wider proximal region, which they
called the cave region. The results of biochemical studies, includ-
ing competition with the substrate nitroceﬁn and the ﬂuorescent
cross-linking dye ﬂuorescein-5-maleimide (see above), provided
support for the predictions of the docking experiment. Several
studies that employ MD simulations to study the mechanism
of substrate recognition and extrusion in AcrB and MexB have
been reported. For example, MD simulations have been used to
examine the mechanism of the peristaltic action of AcrB (Schulz
et al., 2010; Yao et al., 2010; Fischer and Kandt, 2013; Schulz
et al., 2015), to map the path of substrate from the periplasm to
the central cavity (Imai et al., 2011), to study the role of water
in substrate extrusion (Schulz et al., 2011) and proton transfer
in the transmembrane domain (Fischer and Kandt, 2011), and
the role of a key residue Phe 610 in extrusion (Vargiu et al.,
2011). Several of these studies have been reviewed previously
(Ruggerone et al., 2013a,b; Fischer et al., 2014). Because of the
limitations posed by docking, MD simulations have been used
to study substrate binding and speciﬁcity of AcrB (Vargiu and
Nikaido, 2012; Yao et al., 2013) and MexB (Collu et al., 2012).
In particular, Vargiu and Nikaido (2012) used MD simulations
to examine the interaction between nine substrates and the distal
binding pocket of AcrB in terms of the binding energy, hydropho-
bic surface-matching, and the residues involved in the process.
Despite the potential inaccuracies resulting from the limitations
of the system, the MD simulations enabled the assessment of the
contribution of various residues in ligand binding and produced
a muchmore realistic picture of the interaction of various ligands
with AcrB, as compared to docking. These limitations include the
following: (1) an inability to model the eﬀect of the local envi-
ronment in the binding site on the charge states of substrates, (2)
the diﬃculties in estimating binding aﬃnities due to the intrin-
sic limitations of the methodology used to calculate force ﬁelds,
and (3) the absence of accessory proteins, such as AcrA (Nikaido,
2011) and AcrZ (Hobbs et al., 2012; Du et al., 2014), which may
be required to form the active conformation of AcrB. The major
advantages of the MD simulations include the presence of water
molecules in the simulation and the ﬂexibility of the distal bind-
ing site, which enables the modeling of binding interactions that
are more realistic. For example, the binding site predicted for
the bile salt taurocholate by MD simulations was similar to the
one predicted by docking. However, MD simulation oriented the
compound so that the hydrophobic and hydrophilic groups on
the diﬀerent sides of the planar structure were facing hydropho-
bic binding site residues or the solvent ﬁlled channel, respectively.
Strong interactions between water molecules and most of the
other substrates were observed, which are indicative of a more
realistic binding prediction. This is illustrated by the binding pose
of minocycline that was predicted by the MD simulation, which
was in very good agreement with the crystallographic structure
(Murakami et al., 2006; Eicher et al., 2012). The results of these
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MD simulations demonstrate that this is a promising approach
for studying substrate binding to RND-family pumps.
Computational models have also been used to study the inter-
actions between EPIs and AcrB. The docking studies reported
by Takatsuka et al. (2010) included the EPI NMP, which was
predicted to bind to the “cave” region (see above) of distal bind-
ing pocket. Because of the low resolution of the docking model,
Vargiu and Nikaido (2012) used MD simulations to study the
interaction of NMP and PAβN with AcrB (see Figures 3C,D).
The results of the MD simulations for the EPIs NMP and PAβN
were markedly diﬀerent from those of the substrate compounds
that were included in the study. The EPIs were predicted to bind
to a site that included the so-called “G-loop” or “switch loop”
(Nakashima et al., 2011; Eicher et al., 2012; Cha et al., 2014),
which separates the distal and the proximal binding sites and is
thought to be involved in the movement of substrates from the
proximal to the distal site. In addition, the high resolution of
the MD simulations enabled the identiﬁcation of the amino acid
residues that contributed to the binding energy. Recently, MD
simulations have been used to evaluate the interaction between
MBX2319 (see Figure 3A), a novel pyranopyridine EPI, and AcrB
(Opperman et al., 2014). MBX2319 is predicted to bind to the
same “hydrophobic trap” that was identiﬁed in the X-ray cocrys-
tal structure of D13-9001 and AcrB (Nakashima et al., 2013). The
data suggests that these compounds may share a common MOA.
Based on the Gb values, the relative binding aﬃnities of the
EPIs were as follows: D13-9001 > MBX2319 > NMP and PAβN,
which is consistent with their relative potencies as EPIs. Finally,
FIGURE 3 | Molecular dynamic simulations of efflux pump inhibitors
and minocycline (MIN) to the distal substrate binding pocket of the
Binding protomer of AcrB. The position of the various ligands used in this
study with respect to the hydrophobic trap in protomer B in representative
average structures of the complexes from MD simulations are shown. The
structures of the ligands are depicted as stick drawings that colored
according to the atom type (red, oxygen; yellow, sulfur; dark blue, nitrogen;
cyan, carbon; white, hydrogen). The side chains of residues constituting the
hydrophobic trap are depicted as stick drawings (thick if the residue is within
3.5 Å of the ligand, thinner otherwise). The rest of the protein is shown with
molecular surface, colored in orange, yellow and iceblue at the PC1/PC2
Cleft, the G-loop tip and the exit Gate, respectively, and white elsewhere.
The channels leading to the proximity of the exit Gate (see Figure 1) and
passing through residues of the DP are also shown in the presence and in
the absence of the ligand, respectively, are shown as blue and green
transparent surfaces. The centers of gravity of the points defining them are
shown with points. The centers of mass of the access binding pocket (AP)
and of the distal pocket (DP) are shown with green and red transparent
spheres, respectively. No contiguous substrate translocation channel was
found in the AcrB-PAβN complex (D). The ligands are shown in the following
panels: (A) MBX2319; (B) D13-9001; (C) NMP; (D) PAβN; (E) MIN. (F) The
substrate translocation channel of AcrB is shown in the ligand-free state to
illustrate the representative average structure of the transporter. This figure
was taken from Vargiu et al. (2014) and was modified slightly.
Frontiers in Microbiology | www.frontiersin.org 8 May 2015 | Volume 6 | Article 421
Opperman and Nguyen Efflux pump inhibitor mechanism
the computational protocol was able to reproduce the binding
of minocycline and D13-9001 to AcrB that was observed in co-
crystal structures with RMSD values of 2.7 ± 1.0 and 2.8 ± 0.4 Å
(see Figures 3B,E), respectively, which increases the level con-
ﬁdence in the modeling results. Therefore, MD simulation is a
promising approach to generate molecular hypotheses for the
MOA of EPIs.
An Overview of the Major Classes of EPIs
and their Mechanism of Action
In this section, we will brieﬂy review the important classes of
EPIs that are active against the RND-family eﬄux pumps of
Gram-negative bacteria. This section provides an overview of
the biological activities of each EPI class and drug development-
related issues (where appropriate). In addition, we will review the
mechanistic action studies for each compound class.
Peptidomimetic EPIs: PAβN and the C-Capped
Dipeptide Analogs
Renau et al. (1999), researchers at Microcide Pharmaceuticals
and Daiichi Pharmaceutical Co. reported their discovery of the
ﬁrst inhibitor of RND transporters of Gram-negative bacteria,
phenylalanyl arginyl β-naphthylamide (MC-207,110 or PAβN,
see Figure 4). This dipeptide compound was identiﬁed as a
promising hit from a screening of 200,000 samples for small
molecules that potentiate the antibacterial activity of levoﬂoxacin
against strains of P. aeruginosa overexpressing MexAB, MexCD,
and MexEF pumps.
In vitro/spectrum of co-antibiotics
The EPI activity of PAβN is strongly dependent on the nature of
the antibiotic used as an indicator of pump activity, as measured
as a shift in the MIC of the antibiotic (Lomovskaya et al., 2001).
Speciﬁcally, at 20 μM concentration, the potentiating eﬀect of
PAβN on levoﬂoxacin and erythromycin against a strain over-
expressing MexAB-OprM was comparable to that of a MexAB-
OprM deﬁcient strain. It also exhibited strong potentiation for
chloramphenicol, but only weak potentiation for carbenicillin,
and none for ethidium bromide, one of the known substrates of
MexAB-OprM pump. PAβN did not potentiate antibiotics that
are not substrates of MexAB-OprM pump, such as gentamicin
and imipenem.
Other biological assays (Lomovskaya et al., 2001) showed that
PAβN also inhibits eﬄux of the AcrAB-TolC pump of E. coli,
however, it is not very potent against this organism (Opperman
et al., 2014). While PAβN did not aﬀect the proton gradient
across the inner membrane, it increased permeability of the outer
membrane of the PAM2035 strain, which lacks the functional
MexAB-OprM pump, in a dose dependent manner. The per-
meabilizing eﬀect of PAβN was due to its dicationic character.
However, the outer membrane activity was abolished by addition
of magnesium salt. Although the eﬀect on membrane integrity of
PAβN is less than that of polymyxin B, it is a toxicity concern.
Scaﬀold optimization
Because PAβN is not very potent and unstable in murine and
human serum, Renau et al. (1999, 2001) prepared over 500
analogs of PAβN aiming to improve the potency (measured by
Minimum Potentiation Concentration that decreases the MIC
by 8-fold (MPC8) with levoﬂoxacin) and serum stability. For
structural optimization, the scaﬀold was divided into three parts:
amino acid 1 and 2 (AA1, AA2) and the (amide) cap (Figure 4).
Some of the main ﬁndings are: (i) an amino acid containing a
basic side chain (as either AA1 or AA2) is needed for activity; (ii)
Orn could replace Arg; (iii) replacement of Phe with homoPhe
led to improved potency; (iv) methylation of the NH that links
AA1 and AA2 led to increased serum stability; (v) replace-
ment of L-amino acid with D-amino acid is acceptable and led
to increased serum stability; (vi) replacing β-aminonaphthalene
with 3-aminoquinoline as the cap group led to slightly reduced
potency, but also less intrinsic antibacterial activity and less cyto-
toxic to mammalian cells. Overall, the analogs did not seem to
be much more potent than PAβN (the lowest MPC8 = 2.5 μM
for some compounds), but the stability in serum was signiﬁcantly
improved, enabling in vivo testing.
In vivo activity
Two analogs were selected for in vivo eﬃcacy testing (Figure 4)
that showed signiﬁcant reduction on the growth of P. aeruginosa
in a murine neutropenic thigh model when used in combination
with levoﬂoxacin (Renau et al., 1999, 2001). Speciﬁcally, com-
pound L-Phe-(Me)-L-Orn-β-Na at 30 mg/kg (intraperitoneally)
in combination with levoﬂoxacin (30 mg/kg, subcutaneously) led
FIGURE 4 | Structures of PAβN and selected analogs.
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to 3-log reduction in colony forming units (cfu) for approxi-
mately 4 h, followed by regrowth. A single dose of either lev-
oﬂoxacin or test compound resulted in growth similar to the
untreated controls. The immune-suppressed mice in this experi-
ment were infected with P. aeruginosa PAM 1032 (1.0 × 105 cfu,
intramuscularly).
Mechanism of action
The vast majority of the MOA studies for this class of EPIs
has been done using PAβN. Lomovskaya et al. (2001) demon-
strated that PAβN is a substrate for RND pumps of P. aeruginosa
(MexB, MexD, and MexF), suggesting that it acts as a compet-
itive inhibitor of substrate binding and/or extrusion. PAβN has
been shown to increase the susceptibility of a MexAB-OprM-
overproducing strain of P. aeruginosa to a wide range of antibi-
otics, such as levoﬂoxacin, sparﬂoxacin, chloramphenicol, and
erythromycin. However, it was signiﬁcantly less eﬀective when
combined with tetracycline, carbenicillin, and ethidum bromide.
If PAβN is a competitive inhibitor, the spectrum of antibiotic
potentiation may suggest that the binding sites of PAβN may
not overlap with these compounds. To date, there have been no
reports of the isolation of mutants with reduced susceptibility to
PAβNwith mutations that map to an RND-encoding pump gene.
Because of the lack of experimental evidence to shed light on
the molecular mechanism of the EPI activity of PAβN, Vargiu
and Nikaido (2012) used MD simulations to examine the inter-
action between PAβN and AcrB. As mentioned above, the results
of MD simulation experiments predict that PAβN binds with
a relatively low aﬃnity to the distal substrate binding site of
AcrB and straddles the G-loop. PAβN is predicted to interact
mainly with the hydrophobic residues F136, F178, F615, and
F628, but may interact with the hydrophilic residues Q176 and
E673. Binding of PAβN is predicted to cause a conformational
change that shrinks the substrate extrusion channel in the distal
binding pocket, which is where many substrates bind. Therefore,
the results suggest two possible mechanisms, which may not
be mutually exclusive. First, PAβN prevents movement of the
G-loop, which plays an important role in the movement of sub-
strates from the proximal to the distal binding sites (Eicher et al.,
2012; Cha et al., 2014). Second, the conformational change in
the substrate extrusion channel prevents the binding of other
substrates to this site. A docking study suggested that the con-
formational change induced by PAβN reduced the aﬃnity of
minocycline (Vargiu et al., 2014), which supports the second
possible MOA.
The ﬁrst detailed description of the biological activity of
PAβN demonstrated that it has the additional MOA of alter-
ing the permeability of the outer membrane (Lomovskaya et al.,
2001), although PAβN was less potent (half maximal eﬀect at
∼70 μg/ml) than the polymyxin B nonapeptide (PMBN), an
outer membrane-speciﬁc permeabilizing agent (Vaara and Vaara,
1983) that was used as a positive control. The increase in outer
membrane permeability is expected to result in increased inﬂux
of antibiotics into the periplasm, which would increase suscepti-
bility to an antibiotic substrate in an eﬄux-independent manner.
However, the outer membrane activity of PAβN was abolished by
the addition of 1 mM Mg2+, but it is not clear whether Mg2+
was eﬀective at higher concentrations of PAβN. The outer mem-
brane activity of PAβN and the eﬀect Mg2+ was also described
recently by Lamers et al. (2013). Therefore, experiments with
PAβN should include 1 mM Mg2+ to minimize the eﬀect of the
outer membrane activity.
1-(1-Naphthylmethyl)-Piperazine (NMP) and the
Arylpiperazine Analogs
Bohnert and Kern (2005) reported the discovery of 1-(1-
Naphthylmethyl)-piperazine (NMP, Figure 5) as an EPI against
E. coli. The authors screened a library of N-heterocyclic com-
pound library for potentiators of levoﬂoxacin against E. coli
strains overexpressing acrAB and acrEF (2-DC14PS and 3-
AG100MKX, respectively) and found some phenylpiperazine
derivatives with activity. Further SAR study led to the synthesis
of NMP, one of the most potent analogs. NMP (at 100 μg/mL)
caused an increase in the intracellular accumulation of lev-
oﬂoxacin. It also caused accumulation of ethidium bromide in a
dose dependent manner (6.25–100 μg/mL) in the pump overex-
pressing strains (2-DC14PS and HS414), but not in the pump-
deﬁcient strains (1-DC14PS and HS276), suggesting it was an
inhibitor of the AcrAB and AcrEF eﬄux pumps. Because of low
potency and the possibility that NMP acts as serotonin ago-
nist, the likelihood that this EPI will be developed further as a
adjunctive therapeutic agent is low (Zechini and Versace, 2009).
At 100 μg/mL concentration, against E. coli strains over-
expressing acrAB or acrEF, NMP potentiated levoﬂoxacin
by 8- to 16-fold, and by 4- to 8-fold for oxacillin, rifampin,
chloramphenicol, and clarithromycin. It reduced the MIC of
linezolid against the acrEF-overexpressing strain (2-DC14PS) by
32-fold, and by 8-fold against the acrAB-overexpressing strain
(3-AG100MKX). Other ﬂuoroquinolones (ciproﬂoxacin, nor-
ﬂoxacin, enoxacin, and peﬂoxacin), erythromycin, azithromycin,
clindamycin, doxycycline, and nitrofurantoin, but not the
ketolide telithromycin, glycopeptides, aminoglycosides,
trimethoprim-sulfamethoxazole, and fosfomycin were potenti-
ated by NMP (at 100 μg/mL), as indicated by ≥4-fold reduction
of MIC against the 3-AG100MKX strain.
Testing against 60 clinical isolates of E. coli using NMP at
100 μg/mL showed that this compound was moderately active
in reversing MDR in clinical isolates of E. coli and could partially
restore ﬂuoroquinolone susceptibility (Kern et al., 2006). NMP
caused reduction of MICs of levoﬂoxacin, linezolid and ethidium
bromide by ≥4-fold in >50% of the isolates. Although its poten-
tiation of linezolid was notable, the eﬀect was not enough to make
FIGURE 5 | Structure of NMP.
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the isolates susceptible to this antibiotic. NMP also showed par-
tial MDR reversal eﬀects against other Enterobacteriaceae species,
e.g., E. aerogenes and K. pneumonia (Schumacher et al., 2006),
and Acinetobacter baumannii (Pannek et al., 2006). It was noticed
that NMP and PAβN showed markedly diﬀerent preferences for
antibacterial agents, as well as, the isolates that each could work
with, suggesting they might inhibit diﬀerent pumps, bind to
diﬀerent sites of the same pump(s), or act on diﬀerent target(s).
Mechanism of action
1-(1-Naphthylmethyl)-piperazine is widely used as a research
reagent. Consequently, there is great interest in the MOA of this
compound. Schuster et al. (2014) were the ﬁrst group to suc-
cessfully isolate AcrB mutants resistant to NMP. They screened
a library of mutants in which the substrate binding and extrusion
domain of AcrB were randomly mutagenized using error-prone
PCR for mutants that were able to form colonies on plates con-
taining NMP and linezolid. The authors isolated several mutants
with reduced susceptibility to NMP that did not decrease func-
tion of the pump. Site-directed mutagenesis of wild-type acrBwas
used to verify the genetic basis for the NMP-resistant phenotype.
Only a double mutant, in which Gly141 was substituted with Asp
(G141D) and Asn282 was substituted with Tyr (N282Y), signif-
icantly aﬀected susceptibility to NMP. The mutated residues are
located near the outer face of the distal substrate binding pocket
near Phe610 (see Figure 1A), which plays an key role in the extru-
sion process (Bohnert et al., 2008) and is across from the G-loop
that separates the proximal (access) and the distal (substrate)
binding sites (Nakashima et al., 2011; Eicher et al., 2012). The
authors speculate that G141D N282Y amino acid substitutions
prevent binding of NMP at a site near Phe610, where NMP is pre-
dicted to alter the speciﬁcity or the conformational changes of the
binding pocket by acting on Phe610 in a non-competitive man-
ner (see below). Interestingly, the NMP resistant phenotype was
observed only in the presence of linezolid, and partial resistance
in the presence of Hoechst 33342 and levoﬂoxacin. The reason
for this is unclear. However, as mentioned above, it is possible
that the NMP resistant mutant enables the extrusion of linezolid
when NMP is bound to a site that straddles the G-loop, which
was predicted by MD simulations (see Figure 3C; Vargiu and
Nikaido, 2012; Vargiu et al., 2014). The estimated binding energy
is −10.6 ± 7.9 kcal/mol. The NMP binding site includes inter-
actions with hydrophobic residues near the hydrophobic patch
(F664 and F666) and G617 of the G-loop. This suggests the NMP
inhibits the action of AcrB by interfering with the movement
of the G-loop, which has been shown to play important role in
the extrusion of certain substrates (Eicher et al., 2012; Cha et al.,
2014). As shown in Figure 1A, the binding site for NMP that was
predicted by MD simulations does not include G141 and N282.
Also, as is the case for PAβN, NMP is predicted to induce a con-
formational change that results in a reduction of the width of
the substrate binding cleft (Vargiu and Nikaido, 2012). Therefore,
the amino acid substitutions in the NMP resistant mutant may
prevent these NMP-induced conformational changes, allowing
extrusion of linezolid when NMP is bound.
Despite the fact that NMP is used widely as a research reagent,
two important questions about its activity have not been resolved.
It has been stated in the literature that NMP is not a substrate
of RND-family pumps, however, convincing data to support this
statement have not been published. For example, Schuster et al.
(2014) reported that the rate of intracellular accumulation of
NMP (100 μg/ml) was similar in an AcrB overexpressing strain,
an AcrB-deﬁcient strain, and NMP resistant mutants. Based on
this result, the authors concluded that NMP is not a substrate (or
a poor substrate) of AcrB (Schuster et al., 2014). However, the
data was not presented in their paper. As discussed in the next
section, these types of assays must be interpreted with caution
when high concentrations of an EPI are present in the medium.
Therefore, is not a trivial matter to determine whether an EPI
is a substrate or non-substrate of an RND-family pump. Unlike
PAβN, additional mechanisms of action for NMP have not been
reported. However, NMP exhibits antibacterial activity at a con-
centration of 400 μg/ml (Bohnert and Kern, 2005), which is only
4-fold higher than the concentration at which it is used as an
EPI. This indicates that this compound acts on an additional
cellular target, resulting in growth inhibition. The most likely
secondary target of NMP is the membrane, however, the eﬀect
this compound on membrane potential or integrity has not been
reported.
D13-9001 and the Pyridopyrimidinone Analogs
Yoshida et al. (2007) at Daiichi Pharmaceutical Co. and Essential
Therapeutics described D13-9001 (Figure 6) as a MexAB-OprM
speciﬁc pump inhibitor against P. aeruginosa with good solubil-
ity and in vivo activity. This report was the last of a seven article
series starting from 2003, describing a systematic optimization
of another screening hit compound (D1, Figure 6; Nakayama
et al., 2003a,b, 2004a,b; Yoshida et al., 2006a,b). Compound D1
FIGURE 6 | Structure of D13-9001 and its developmental precursors.
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only inhibited MexAB-OprM pump, and not the MexCD-OprJ,
MexEF-OprN, or MexXY-OprM pumps. It exhibited very good
MPC8 with levoﬂoxacin (≤0.63 μM) against a P. aeruginosa
strain (PAM1723) that has overexpressed MexAB-OprM and
disrupted MexCD-OprJ and MexEF-OprN. However, this com-
pound was practically insoluble in water and showed no eﬃcacy
in vivo.
The poor in vivo performance of D1 was attributed to its
high aﬃnity for serum albumin (>98% protein bound) and the
increase in MPC8 (>10-fold shift) when serum was added. After
some unsuccessful attempts at conservatively modifying the scaf-
fold to improve pharmacokinetic properties, big changes were
made by installing the quinolone and pyridopyrimidinone frag-
ments to the mid-section of the scaﬀold. The pyridopyrimidinone
analogs, such as D2, displayed higher MPC8 as compared to D1
(5 μg/mL for aztreonam and 10 μg/mL for levoﬂoxacin), but
had lower aﬃnity to serum protein and were eﬀective in vivo
(Nakayama et al., 2003b). Subsequent eﬀorts to further optimize
the scaﬀold for activity and pharmacokinetic properties led to
the synthesis of D13-9001. This zwitterionic compound was sol-
uble enough for iv administration (747 μg/mL in pH 6.8 buﬀer),
exhibited MPC8 = 2 μg/mL for levoﬂoxacin and aztreonam
against the PAM1723 strain of P. aeruginosa. D13-9001 demon-
strated acceptable PK proﬁles in rats and monkeys. It did not
alter the serum level of aztreonam when both were given by iv
(1000 mg/kg of aztreonam T, 1.25–20 mg/kg of D13-9001, 2 h
infusion). In a lethal pneumonia model in rats (using PAM1020
strain), in combination with aztreonam (1000 mg/kg) D13-9001
(at 1.25–20 mg/kg) showed improved survival rates at the end of
day seven.
Mechanism of action
Nakashima et al. (2013) reported that D13-9001 does not per-
turb the inner or the outer membranes. In this same paper, the
authors determined that D13-9001 is not a substrate of AcrB.
They measured the time-dependent change in concentration of
D13-9001 in the media containing either an AcrB overexpressing
or an AcrB-deﬁcient strain. Compounds that are not substrates
accumulate in both strains, resulting in a decrease compound
concentration in the media, while pump substrates will accumu-
late only in the AcrB-deﬁcient strain. Using this assay, the authors
concluded that D13-9001 is not a substrate. However, results of
this nature should be interpreted with caution when the test com-
pound is a potent EPI and is present at a high concentration
(28.6 μM) in the medium. The high concentration of EPI is likely
to inhibit AcrB, causing compound to accumulate in the AcrB
overexpressing strain. Thus, potent EPIs would appear to be non-
substrates, even when they are actually pump substrates. At this
point, it is not clear whether D13-9001 is a non-substrate. This
situation underscores the diﬃculties at present in determining
whether EPIs are substrates using the available assays.
As mentioned above, Nakashima et al. (2013) elucidated the
three-dimensional structure of the EPI D13-9001 bound to AcrB
and MexB. The hydrophobic tert-butyl thiazolyl aminocarboxyl
pyridopyrimidine moiety of D13-9001 binds tightly to a nar-
row depression, referred to as the hydrophobic trap, in the
deep substrate binding pocket in the “Binding” protomer (see
Figures 2A,B). The hydrophobic trap branches oﬀ from the
substrate translocation channel and is lined with hydrophobic
residues (F136, F178, F610, F615, and F628). In addition, the
tetrazole ring and the piperidine aceto-amino ethylene ammonio-
acetate moiety interact with ionic and/or hydrophilic residues
(N274, R620, Q176, and S180 in addition to aliphatic residues
(I277 and L177) that are in the substrate translocation channel.
The piperidine aceto-amino ethylene ammonio-acetate moiety
extends into the substrate binding sites of both minocycline and
doxorubicin. The crystal structure of the D13-9001 binding site
in MexB was found to be similar to the binding site in AcrB,
except that the conformation of the PAEA moiety in the sub-
strate translocation channel was diﬀerent. A homology model
of the three-dimensional structure of MexY predicted that D13-
9001 would not bind because F178 at the edge of the hydrophobic
trap of AcrB/MexB has been replaced with a bulky W177 in
MexY, which is predicted to prevent binding by steric hindrance.
The model was conﬁrmed when a site-directed mutant of MexY
(W177F) was shown to be sensitive to inhibition by D13-9001.
Conversely, D13-9001 does not bind to AcrB (F178W). As shown
by ITC, D13-9001 binds tightly to AcrB andMexBwith KD values
of 1.15 and 3.57 μM, respectively. It is possible that the successful
production of co-crystals with D13-9001 is due to the high aﬃn-
ity of this compound for AcrB and MexB. This EPI inhibits eﬄux
of a broad range of compounds, presumably not by competi-
tive inhibition (yet to be determined experimentally). The current
hypothesis is that D13-9001 binds tightly to the hydrophobic trap
and prevents the conformational changes that are needed for the
proper activity of the pump (Nakashima et al., 2013). In addition,
the presence of the hydrophilic portion of this EPI in the sub-
strate binding channel is predicted to prevent substrate binding
to this site. Therefore, this study hasmade a signiﬁcant advance in
the understanding of the mechanism of inhibition of an EPI, and
has identiﬁed a previously unknown binding site in RND pumps
that can be exploited for the rational design or optimization of
EPIs. Because MD simulations (see Figure 3B) have been able to
reproduce the structure of D13-9001 bound to AcrB (rmsd 2.8 Å;
Vargiu et al., 2014), this tool may prove to be useful in evaluating
novel EPIs.
Pyranopyridines (MBX2319)
Opperman et al. (2014) at Microbiotix reported compound
MBX2319 (Figure 7) as a novel inhibitor of the AcrAB eﬄux
pump of E. coli. It was discovered from a high-throughput
FIGURE 7 | Structure of MBX2319.
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screening campaign designed to look for small molecules that
potentiate ciproﬂoxacin against E. coli. Because the authors were
not speciﬁcally looking for eﬄux inhibitors, the bacterial strain
was not engineered to overexpress any transporters. MBX2319
had no intrinsic antibacterial activity (MIC ≥ 100 μg/mL), but
exerted signiﬁcant potentiating eﬀects on antibiotics that are
substrates of AcrB, such as ﬂuoroquinolones, β-lactams, chloram-
phenicol, erythromycin, and linezolid at concentrations of 3.1–
12.5 μg/ml. Consistent with the proposed mechanism, MBX2319
did not aﬀect MICs of antibiotics against acrB-deleted mutant or
of antibiotics that are not AcrB pump substrates, e.g., gentamicin
and carbenicillin. Further, MBX2319 caused increased intracellu-
lar accumulation of dye Hoechst 33342 and nitroceﬁn in a dose
dependent manner in wild-type E. coli strains, but not the acrB
and tolC strains. This inhibitor also worked against other
Enterobacteriaceae species, i.e., Shigella flexneri, K. pneumoniae,
S. enterica and E. cloacae. Against P. aeruginosa (ATCC 27854),
MBX2319 reduced the MIC of cefotaxime (but not ciproﬂoxacin
or levoﬂoxacin) ca. 6-fold. However, the observation that PMBN
increases the EPI activity of MBX2319 against P. aeruginosa
indicates the outer membrane of this organism is the major
obstacle to activity (Opperman et al. manuscript in prepara-
tion). Therefore, the pyranopyridines have the potential to be
used as an adjunctive therapy against both Enterobacteriaceae
and P. aeruginosa.
Mechanism of action
Based on the results of MD simulations, MBX2319 is predicted to
bind to the same “hydrophobic trap” (see Figure 3A) that was
identiﬁed in the X-ray crystal structure of D13-9001 bound to
AcrB (Nakashima et al., 2013). The pyridine ring of MBX2319
is predicted to make a ring-stacking interaction with the rings
of F628 on one side and F136 on the other. The morpholinyl
moiety is predicted to be in close proximity to Y327, and the
phenylethylthiol group is loosely located in a hydrophobic pocket
surrounded by F610, F628, P326, and Y327 (see Figure 3A). The
prevalence of interactions with aromatic or aliphatic residues
results in a calculated Gb of −12.5 kcal/mol. Indeed, almost
70% of Gsolv comes from residues belonging to the hydropho-
bic trap. As this region undergoes large conformational changes
during the functional rotation of AcrB, binding of MBX2319
with high aﬃnity could hinder these rearrangements (or those
triggering the translocation of protons from the periplasm to
the cytoplasm upon substrate binding). In addition, as a result
of the interaction with the hydrophobic trap, the part of the
distal binding site that forms a cleft, which is the binding site
for minocycline and doxorubicin appears to shrink (compare
Figures 3A–F), which may inhibit substrate binding. Indeed,
results from the cell-based nitroceﬁn eﬄux assay (described
above) demonstrated that at 0.2 μM MBX2319 increased the
apparent Km of AcrB for nitroceﬁn by >4-fold (Opperman et al.,
2014), suggesting, that the EPI altered the aﬃnity of the substrate
for AcrB. Thus, the results of MD simulations are consistent with
those of crystallographic methods and can be useful for the gen-
eration of molecular hypotheses for the MOA of EPIs that can be
tested using genetic and biochemical experiments.
The EPI activity of MBX2319 appears to be speciﬁc for RND
pump inhibition. MBX2319 does not exhibit intrinsic antibac-
terial activity (MIC ≥ 100 μM), so it is unlikely to act on a
secondary non-speciﬁc target, such as the inner or outer mem-
brane. This possibility is supported by experimental results that
demonstrate MBX2319 does not perturb the proton gradient
or integrity of the inner membrane, nor does it increase the
permeability of the OM (Opperman et al., 2014).
Future
Recent advances in methodologies have led to a greater under-
standing of the MOA of EPIs. In particular, the elucidation of
a three-dimensional structure of the EPI D13-9001 bound to
AcrB has resulted in hypotheses for the MOA of this compound.
In addition, this structure has identiﬁed a previously unknown
binding site of EPIs in the distal binding pocket, known as the
hydrophobic pocket, which can be exploited for the rational
design and optimization of novel EPIs with improved potency
and spectrum of activity. Due to recent advances in technol-
ogy, MD simulations have been able to reproduce the binding of
two substrates and an EPI elucidated by crystallographic stud-
ies with a high degree of accuracy. This raises the possibility
that this method could be used to evaluate novel inhibitors.
Together, these advances could be useful in overcoming some of
the major challenges in the discovery and development of clin-
ically useful EPIs. One of the major challenges in the design of
EPIs for Gram-negative is to make compounds that are able to
traverse the OM and can bind to the RND pumps with high
aﬃnity. Penetration of the OM is controlled by porins, which pre-
fer smaller hydrophilic and zwitterionic molecules. In contrast,
the major RND pumps prefer larger hydrophobic molecules. By
using rational drug design, however, it will be possible to iden-
tify suitable positions on EPIs to append charged groups that will
improve OM penetration but will not decrease aﬃnity for the
pump.
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